SCHEMBL4521185

SCHEMBL4521185

O=C(NCC1CCCCC1)c1ccccc1N1CCN(C(=O)[C@@H](Cc2ccc(Cl)cc2)N2[CH]Cc3ccccc3C2)CC1

nearest known ligand 0.40

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
MC4R P32245 13/20 0.40
CNR1 P21554 3/20 0.40
NAMPT P43490 1/20 0.39
MAPK14 Q16539 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784715 0.86 MC4R (0.45) MC4R
SCHEMBL4683042 0.85 MAPT (0.46) MC4RNAMPT
SCHEMBL4677982 0.85 MC4R (0.43) MC4R
SCHEMBL4685109 0.77 MC4R (0.42) MC4R
SCHEMBL4681379 0.77 MC4R (0.49) MC4R
SCHEMBL5482741 0.77 MC4R (0.62) MC4R
SCHEMBL5482747 0.76 MC4R (0.47) MC4R
SCHEMBL4681339 0.76 MC4R (0.47) MC4R
SCHEMBL4681085 0.76 LMNA (0.47) MC4R
SCHEMBL4684460 0.72 MC4R (0.55) MC4R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7560460-B2 Substituted piperazines and methods of use AMGEN INC. (US) 2009-07-14 US disclosed
EP-1417190-B1 SUBSTITUTED PIPERAZINES AS MODULATORS OF THE MELANOCORTIN RECEPTOR AMGEN INC (US) 2008-10-22 EP disclosed
US-20070265248-A1 Substituted piperazines and methods of use AMGEN INC. (US) 2007-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265248-A1 Substituted piperazines and methods of use MC5R, MC4R, MC1R MC4R 2/4885CNR1 105/4885NAMPT 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.